NEW YORK, March 26 (Reuters) - Two experimental Ebolavaccines, one from GlaxoSmithKline PLC and the otherfrom biotech start-up NewLink Genetics Corp, "appear tobe safe" part way through a clinical trial being conducted inLiberia, the U.S. National Institutes of Health (NIH) said onThursday.
The two vaccines, each given in a single injection, arebeing tested for safety and efficacy on more than 600 people inLiberia in a mid-stage clinical trial sponsored by the NationalInstitute of Allergy and Infectious Diseases, a branch of NIH.
The Ebola epidemic that began in West Africa one year agohas killed more than 10,200 people, but a decline in new casesin the most affected countries, Liberia, Guinea and SierraLeone, has led to hopes that it may be ending. (Reporting by Sharon Begley)